AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00186966 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Total body irradiation
Description: See Detailed Description section for details of treatment interventions.
Study NCT00326586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR Antagonist (BMS-641988)
Description: Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
Study NCT01270217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
Study NCT03760770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal collagen crosslinking
Description: Crosslinking in patients with progressive keratoconus.
Study NCT02515097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Medicated topical lotion
Study NCT02515097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Vehicle topical lotion with no active ingredient
Study NCT03994458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Full version application
Description: Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
Study NCT03994458 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Samartphone limited version application
Description: Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
Study NCT00855595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid (Finacea, BAY39-6251)
Description: Participants received topical azelaic acid gel 15% twice daily for 12 weeks
Study NCT00855595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole (Metrogel)
Description: Participants received topical metronidazole 1% gel once daily for 12 weeks
Study NCT00855595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline (Oracea)
Description: Participants received systemic doxycycline 40 mg once daily for 12 week
Study NCT00855595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline (Oracea)
Description: Participants received systemic doxycycline 40 mg once daily for 12 week
Study NCT03114280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF2
Description: Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
Study NCT03114280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy with carboplatin
Description: Radiotherapy (RT) combined with carboplatin
Study NCT00978965 — intervention group
Intervention type: GENETIC
Intervention: MPA SNP
Description: Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
Study NCT03962725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents
Description: Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
Study NCT03962725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetic Adjuncts
Description: Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
Study NCT03141099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
Study NCT03141099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Study NCT03141099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2.
Description: The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Study NCT03141099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is intravenously administrated before anesthesia induction
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is intravenously administrated before anesthesia induction
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol
Description: Butorphanol is intravenously administrated
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil is intravenously administrated
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated
Study NCT03749577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline 9g per day (capsule, per os) during 14 days;
Study NCT03749577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
Study NCT02043366 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil is intravenously administrated
Study NCT02167464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin treatment-guided Therapeutics
Description: Patients are treated based upon their renin levels according to an approved algorithm.
Study NCT03749577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline placebo
Description: L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
Study NCT01275508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FITC-Adalimumab
Description: The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
Study NCT01430403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
Study NCT01430403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid Boost Therapy (ICS)
Description: Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
Study NCT01430403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo omalizumab
Description: Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
Study NCT01430403 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo omalizumab
Description: Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
Study NCT01430403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo fluticasone
Description: Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
Study NCT01430403 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fluticasone
Description: Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
Study NCT02410434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGBT Stigma Reduction Intervention
Description: Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
Study NCT04116658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple dose of EO2401
Description: Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
Study NCT04564378 — intervention group
Intervention type: OTHER
Intervention: This is an observational study. There is no therapeutic intervention.
Description: This is an observational study. There is no therapeutic intervention.
Study NCT03749577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Denitrated beetroot juice
Description: Concentrated 70 ml nitrate-depleted beetroot juice
Study NCT03140501 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile application (app)
Description: The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues.
Study NCT03140501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application (app)
Description: The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues.
Study NCT01106053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
Study NCT03733561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
Study NCT03733561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro 4Mg/24Hr Transdermal Patch
Description: neupro patch
Study NCT01117701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy with and without safety guidewire
Description: In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
Study NCT03261674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Study NCT03261674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABT-I
Description: Arousal-Based Therapy for Insomnia (ABT-I)
Study NCT02167464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral Hypertension specialist
Description: Patients are referred to a hypertension specialist.
Study NCT03732118 — intervention group
Intervention type: DEVICE
Intervention: Eye-tracker Mobile EBT
Description: Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
Study NCT01600222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
Study NCT00058201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT00058201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00058201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT00058201 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: clinical observation
Description: No intervention
Study NCT02206490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone
Description: Randomized controlled trial of naltrexone for Gulf War Illness.
Study NCT02167464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone Antagonist
Description: Spironolactone 12.5 - 25mg daily
Study NCT00940056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ablation of AF
Description: The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care.
Study NCT00940056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
Study NCT00865709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Description: Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
Study NCT00865709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Description: Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
Study NCT01698996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Packing vs No Packing
Study NCT01698996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Packing vs No Packing
Study NCT02250560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study NCT04170166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral subacromial steroid injection
Description: Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
Study NCT02206490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naltrexone
Description: Randomized controlled trial of naltrexone for Gulf War Illness.
Study NCT02206490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: Randomized controlled trial of dextromethorphan for Gulf War Illness
Study NCT02206490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: Randomized controlled trial of dextromethorphan for Gulf War Illness
Study NCT03954743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine
Description: 2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
Study NCT03954743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Description: 2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
Study NCT02693821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin 300 mg per day, orally during 30 days
Study NCT02693821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg per day, orally during 30 days
Study NCT01923805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Vitagel
Study NCT01726855 — intervention group
Intervention type: PROCEDURE
Intervention: vascularized finger dorsal fascial flap
Study NCT02496767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Study NCT02496767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT02496767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Study NCT03041844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency, Low Intensity Ultrasound
Description: Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)
Study NCT03041844 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Applicator
Description: Sham ultrasound applicator
Study NCT01729884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID
Study NCT04563533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose vaccine
Description: Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg.
Study NCT04563533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine
Description: Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg.
Study NCT04563533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose vaccine
Description: Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.